Antagoniste And NotB. Jabbari
List of bibliographic references
Number of relevant bibliographic references: 39.| Ident. | Authors (with country if any) | Title |
|---|---|---|
| 002406 | Rajesh Pahwa [États-Unis] ; Kelly E. Lyons [États-Unis] | Mirtazapine in essential tremor: A double-blind, placebo-controlled pilot study |
| 002449 | William G. Ondo [États-Unis] ; Christine Hunter [États-Unis] | Flumazenil, a GABA antagonist, may improve features of Parkinson's Disease |
| 002450 | Juha-Matti Savola [Finlande] ; Michael Hill [Royaume-Uni] ; Mia Engstrom [Finlande] ; Hannele Merivuori [Finlande] ; Siegfried Wurster [Finlande] ; Steven G. Mcguire [Royaume-Uni] ; Susan H. Fox [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Fipamezole (JP-1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease |
| 002556 | Ergun Y. Uc [États-Unis] ; Gerald A. Dienel [États-Unis] ; Nancy F. Cruz [États-Unis] ; Sami I. Harik [États-Unis] | β-Adrenergics enhance brain extraction of levodopa |
| 002605 | Guy Arnold [Allemagne] ; Klaus Tatsch [Allemagne] ; Eduardo Kraft [Allemagne] ; Wolfgang H. Oertel [Allemagne] ; Johannes Schwarz [Allemagne] | Steele-Richardson-Olszewski syndrome: Reduction of dopamine D2 receptor binding relates to the severity of midbrain atrophy in vivo: 123IBZM SPECT and MRI study |
| 002621 | Johannes Schiefer [Allemagne] ; G. Bernhard Landwehrmeyer [Allemagne] ; Hans-Gerd Lüesse [Allemagne] ; Arne Sprünken [Allemagne] ; Christiane Puls [Allemagne] ; Anna Milkereit [Allemagne] ; Eva Milkereit [Allemagne] ; Christoph M. Kosinski [Allemagne] | Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease |
| 002790 | Drugs to treat autonomic dysfunction in Parkinson's disease | |
| 002834 | Joanne E. Nash [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Characterisation of striatal NMDA receptors involved in the generation of Parkinsonian symptoms: Intrastriatal microinjection studies in the 6-OHDA-lesioned rat |
| 002859 | Anticholinergic therapies in the treatment of Parkinson's disease | |
| 002863 | Amantadine and other antiglutamate agents | |
| 002952 | Susan H. Fox [Royaume-Uni] ; Brian Henry [Royaume-Uni] ; Micheal P. Hill [Royaume-Uni] ; David Peggs [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] | Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct : Evidence from the effects of the Alpha2 adrenoceptor antagonist idazoxan |
| 002980 | Olivier Rascol [France] ; I. Arnulf [France] ; H. Peyro-Saint Paul [France] ; C. Brefel-Courbon [France] ; M. Vidailhet [France] ; C. Thalamas [France] ; A. M. Bonnet [France] ; S. Descombes [France] ; B. Bejjani [France] ; N. Fabre [France] ; J. L. Montastruc [France] ; Yves Agid [France] | Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease |
| 002A96 | Hasmet A. Hanagasi [Turquie] ; Gülüstü Kaptanoglu [Turquie] ; Hüseyin A. Sahin [Turquie] ; Murat Emre [Turquie] | The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa |
| 002B22 | N. A. Leopold [États-Unis] | Risperidone treatment of drug-related psychosis in patients with Parkinsonism |
| 002B40 | C. G. Goetz [États-Unis] ; T. Q. Vu ; P. M. Carvey ; S. Leurgans | Posthypoxic myoclonus in the rat : Natural history, stability, and serotonergic influences |
| 002B94 | A. J. Manson [Royaume-Uni] ; E. Iakovidou [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease |
| 002C95 | J. Wissel [Autriche] ; J. Müller [Autriche] ; G. Ebersbach [Autriche] ; Werner Poewe [Autriche] | Trick maneuvers in cervical dystonia : Investigation of movement- and touch-related changes in polymyographic activity |
| 002D01 | B. Henry [Royaume-Uni] ; S. H. Fox [Royaume-Uni] ; D. Peggs [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; J. M. Brotchie [Royaume-Uni] | The α2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-Parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease |
| 002D09 | S. Spieker [Allemagne] ; P.-A. Löschmann [Allemagne] ; T. Klockgether [Allemagne] | The NMDA antagonist budipine can alleviate levodopa-induced motor fluctuations |
| 002D29 | H. D. Rosas [États-Unis] ; W. J. Koroshetz [États-Unis] ; B. G. Jenkins [États-Unis] ; Y. I. Chen [États-Unis] ; D. L. Hayden [États-Unis] ; M. F. Beal [États-Unis] ; M. E. Cudkowicz [États-Unis] | Riluzole therapy in Huntington's Disease (HD) |
| 002D32 | A. Schrag [Royaume-Uni] ; L. Schelosky [Allemagne] ; U. Scholz [Allemagne] ; Werner Poewe [Autriche] | Reduction of parkinsonian signs in patients with parkinson's disease by dopaminergic versus anticholinergic single-dose challenges |
| 002D88 | F. Le Doze [France] ; M. Moulin [France] ; G.-L. Defer [France] | Meige's syndrome in a patient treated with ranitidine |
| 003088 | J. M. Brotchie [Royaume-Uni] | Adjuncts to dopamine replacement : A pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease |
| 003094 | L. V. Metman [États-Unis] ; P. J. Blanchet [États-Unis] ; P. Van Den Munckhof [États-Unis] ; P. Del Dotto [États-Unis] ; R. Natte [États-Unis] ; T. N. Chase [États-Unis] | A trial of dextromethorphan in Parkinsonian patients with motor response complications |
| 003144 | M. Poyurovsky [Israël] ; M. Schneidman [Israël] ; A. Weizman [Israël] | Successful treatment of fluoxetine-induced dystonia with low-dose mianserin |
| 003160 | K. A. Gwinn [États-Unis] ; J. N. Caviness [États-Unis] | Risperidone-induced tardive dyskinesia and parkinsonism |
| 003198 | G. Dziewczapolski [Argentine] ; L. B. Menalled [Argentine] ; M. T. Savino [Argentine] ; M. Mora [Argentine] ; F. J. E. Stefano [Argentine] ; O. Gershanik [Argentine] | Mechanism of action of clozapine-induced modification of motor behavior in an animal model of the "super-off" phenomenon |
| 003236 | I. Soykan [États-Unis] ; I. Sarosiek [États-Unis] ; J. Shifflett [États-Unis] ; G. F. Wooten [États-Unis] ; R. W. Mccallum [États-Unis] | Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease |
| 003291 | A. Negrotti [Italie] ; S. Calzetti [Italie] | A long-term follow-up study of cinnarizine- and flunarizine-induced parkinsonism |
| 003377 | L. V. Metman [États-Unis] ; P. J. Blanchet [États-Unis] ; D. De Jong [États-Unis] ; M. M. Mouradian [États-Unis] ; T. N. Chase [États-Unis] | Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease |
| 003407 | D.-E. Shan [Taïwan] ; S.-Y. Kwan [Taïwan] ; H.-H. Ho [Taïwan] ; M.-S. Su [Taïwan] | Belly dystonia induced by levodopa and biperiden in a case of suspected multiple-system atrophy |
| 003412 | A. P. Sempere [Espagne] ; J. Duarte [Espagne] ; F. Garcia [Espagne] ; C. Cabezas [Espagne] ; F. Coria [Espagne] ; L. E. Claveria [Espagne] | An estimate of the risk of movement disorders associated with the chronic use of clebopride |
| 003423 | K. Kieburtz [États-Unis] ; A. Feigin ; M. Mcdermott ; P. Como ; D. Abwender ; C. Zimmerman ; C. Hickey ; C. Orme ; K. Claude ; J. Sotack ; J. T. Greenamyre ; C. Dunn ; I. Shoulson | A controlled trial of remacemide hydrochloride in Huntington's disease |
| 003495 | J. M. Wojcieszek [Canada] ; A. E. Lang | Gestes antagonistes in the suppression of tics : "tricks for tics" |
| 003568 | T. Mendis [Canada] ; E. Mohr [Canada] ; A. George ; I. N. Rusk [Canada] ; P. Gray ; J. D. Grimes | Symptomatic relief from treatment-induced psychosis in Parkinson's disease: an open-label pilot study with remoxipride |
| 003594 | Olivier Rascol [France] ; N. Fabre [France] ; O. Blin ; J. Poulik [France] ; U. Sabatini [France] ; J.-M. Senard [France] ; M. Ane [France] ; J.-L. Montastruc [France] ; A. Rascol | Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease |
| 003655 | R. A. Hauser [États-Unis] ; C. W. Olanow | orobuccal dyskinesia associated with trihexyphenidyl therapy in a patient with Parkinson's disease |
| 003903 | J. M. Brotchie ; I. J. Mitchell ; M. A. Sambrook ; A. R. Crossman | Alleviation of Parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate |
| 003A07 | E. Pourcher ; A.-M. Bonnet ; J. Kefalos ; B. Dubois ; Yves Agid [France] | Effects of etybenzatropine and diazepam on Levodopa-induced diphasic dyskinesias in Parkinson's disease |
| This area was generated with Dilib version V0.6.23. |  |